β3-AR agonists are potential targets for the pharmacotherapy of obesity and diabetes; however, a better understanding of the mechanisms underlying the metabolism of BAT is needed which will advance management of obesity and diabetes. The gene discussed is ADRB3; the disease is obesity disorder.